disease interaction(s) of HIV1 infection with hepatitis B or hepatitis C & non-Hodgkin's lymphoma
Jump to navigation
Jump to search
Introduction
Interactions:
- coinfection of hepatitis B or hepatitis C in patients with HIV1-infection receiving antiretroviral therapy is associated with increased risk for non-Hodgkin lymphoma[1]
Management
- initiate tenofovir or entecavir for treatment of hepatitis B prior to immunosuppressive chemotherapy[2]
- continue tenofovir or entecavir during immunosuppressive therapy & for 6 months after[2]
More general terms
References
- ↑ 1.0 1.1 Wang Q, De Luca A, Smith C et al Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. Annals of Internal Medicine. Oct 18, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27750294 <Internet> http://annals.org/aim/article/2569661/chronic-hepatitis-b-c-virus-infection-risk-non-hodgkin-lymphoma
- ↑ 2.0 2.1 2.2 NEJM Knowledge+ Gastroenterology
Reddy KR, Beavers KL, Hammond SP et al American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):215-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25447850 Review. No abstract available.
Di Bisceglie AM, Lok AS, Martin P et al Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015 Feb;61(2):703-11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25412906 PMCID: PMC5497492 Free PMC article. Review.